INTRODUCTION
There is a body of information regarding urinary tract infections that clinicians need to know. These physicians want to be able to recognize urinary tract infections, determine what patients merit therapy, and, particularly in the cutrent era of diagnostic-related groups, formulate the essential elements of the evaluation. Physicians are also concerned about another practical issue, namely the duration of therapy for a urinary tract infection. This latter concern is the focus of this review.
It is important for clinicians to appreciate that, despite the extensive data that have accumulated during the last 30 years concerning the diagnosis, pathogenesis, epidemiology, localization, atid management of urinary tract infections, there temain many voids in our knowledge precluding precise guidelines for the duration of treatment of urinary tract infections (32) . There are a number of reasons for this. On occasion, investigators have used inappropriate classifications or imprecise definitions and have not evaluated patients with altered host defenses. Some researchers have failed to appreciate the limitations of classifying patients according to traditional presentations, and others have unduly relied on nonstandardized laboratory localization techniques. At a more elementary level, there has also been an inability of both investigators and clinicians to define successful treatment.
Uniform definitions for urinary tract infections, as well as a clinical classification of patients with these disorders, have been available for approximately 10 years (37, 48 (16, 38) . As a result, all data generated from clinical studies that evaluated the duration of drug therapies and classified patients as having cystitis or pyelonephritis (according to the results of the ACB test) must be considered invalid.
Indivisible from the concept of the appropriate treatment duration for a urinary tract infection is the criterion for successful drug therapy. A criterion to assess treatment success becomes readily apparent to the physician who manages a symptomatic patient with bacteremic pyelonephritis. In this clinical setting, therapy is administered to confine the infection, prevent the development of complications (septic shock, adult respiratory distress syndrome, disseminated intravascular coagulation, hematogenous metastases to heart valves and vertebrae), achieve sterility of the kidneys, and hasten resolution of symptoms. The criterion for successful treatment appears less obvious when a physician treats a non-life-threatening urinary tract infection, such as symptomatic bacterial cystitis or an asymptomatic recurrence (relapse) in a patient with subclinical pyelonephritis.
Some researchers consider that successful drug therapy has occurred when the pretreatment uropathogen has been eradicated, even if a reinfection develops. Other investigators define drug efficacy in terms of therapeutic failures, the phenomenon of bacterial relapse. Of note is the fact that it may not be possible to differentiate bacterial relapse from early reinfection caused by the same organism (26) .
Another issue relates to quantitative standards for organism eradication after the introduction of drug therapy. Historically, quantitative criteria for bacteriuria have served both to distinguish symptomatic pyelonephritis, symptomatic cystitis, asymptomatic cystitis, subclinical pyelonephritis, and catheter-related urinary tract infections (or colonization) from contamination and to provide support for these diagnoses (41) . However, there is no standard criterion for the quantitative concentration of bacteriuria in a posttreatment midstream urine specimen that equates with cure. In addition, if the criterion to establish the diagnosis of symptomatic cystitis in an acutely dysuric woman is .102 bacteria per ml, and the fact that very few women can void sterile urine is appreciated, how does the physician define successful therapy, particularly because after drug treatment virtually all women with such infections are asymptomatic (24)? ACUTE SYMPTOMATIC PYELONEPHRITIS Numerous studies indicate that community-acquired, uncomnplicated (no evidence of obstruction) pyelonephritis in women requiring hospitalization can be successfully treated with a 7-to 14-day course of antimicrobial therapy (6, 34, 36) . Antimicrobial treatmeht is initiated by the intravenous route. Oral therapy can usually commence within 4 days. When it is established that the patient can tolerate the oral medication, the patient can be discharged and advised to continue the antimicrobial agent for 6 days in an outpatient setting. There is no evidence that extending the duration of drug treatment achieves a higher cure rate or that patients who experience coexistent bacteremia (without metastatic deposition) require an extended length of therapy (19) . It has been estimated that a study would have to enroll hundreds of patients to be 80% confident of detecting a 10% difference in treatment efficacy if therapeutic programs of extended duration were compared with the standard 10-day treatment duration (19) . Because of the resources that would have to be marshalled to perform such a prospective study and the acceptable therapeutic results attained with 10-day therapy, it would be difficult to justify a definitive study, and it probably will not be performed.
Researchers have not examined treatment durations for women with acute symptomatic pyelonephritis complicated by an obstruction. Traditionally, antimicrobial therapy is initiated when the diagnosis is suspected and is continued for approximately 8 to 10 days after relief of the obstruction.
Young women with acute symptomatic pyelonephritis who do not require hospitalization can be adequately treated with oral antimicrobial agents (1) . Outpatient therapy is restricted to women who are free of nausea and vomiting, have a secure diagnosis, will comply with the treatment program, and have no known structural abnormalities of the urinary tract. The optimum duration of therapy for these patients has not been determined by clinical studies. Until definitive data have been developed, it appears appropriate to use a 10-day course of drug therapy.
Recurrent pyelonephritis in women with nonobstructive disease has traditionally been treated with 2 weeks of antimicrobial therapy (28) . Limited data indicate that some of the patients who relapse will be cured with a subsequent 6-week course of drug treatment (55) . No well-designed, well-executed, randomized, prospective, controlled study has identified the optimum duration of antimicrobial therapy for women with recurrent subclinical pyelonephritis (31) .
Drug treatment for women with recurrent pyelonephritis complicated by a renal stone or papillary necrosis has been consistently ineffectual (9) . The preferred therapy for these patients includes surgical removal of urinary stones, if possible, and protracted administration of an antimicrobial agent.
The preferred treatment duration for men with acute symptomatic bacterial pyelonephritis has not been defined by controlled, comparative clinical studies. These patients often demonstrate anatomic and neuromuscular abnormalities and, on occasion, harbor deep-seated foci of infection in the prostate. Unimpressive cure rates after 10 to 14 days of therapy are undoubtedly explained by these complicating features (17) . Whether an extended course of treatment would achieve a higher cure rate remains to be determined. This is a particularly important concept for elderly patients, because they do not appear to tolerate antimicrobial agents as well as younger adults (22) .
ACUTE BACTERIAL CYSTITIS IN WOMEN
Before 1967, a 7-to 14-day, multiple-daily-dose regimen of an oral antimicrobial agent was standard therapy for the outpatient management of young women with acute, uncomplicated, symptomatic bacterial cystitis. In the last 19 years, however, a number of investigators have reassessed the need to administer antimicrobial agents for this long a period, and they have suggested that shorter courses of treatment (1, 3, or, perhaps, 4 days) are preferable. The rationale for considering a reduced treatment duration for acute symptomatic cystitis stems from the concept that the high urinary concentrations achieved by oral antimicrobial agents could be expected to eradicate cystitis, a superficial mucosal infection (15) . An impetus for exploring abbreviated treatments was the observation that when symptoms abated patients often discontinued therapy prematurely.
Single-dose therapy has been the most intensively evaluated short-course treatment. There are obvious advantages to this therapeutic program: enhanced compliance, reduced cost and side effects, and lessened selective microbial pressure on the periurethral and rectal tissues. Another potential value of single-dose treatment of acute bacterial cystitis (diagnosed by conventional clinical criteria) is that failure to achieve an immediate bacteriologic response, determined by persistent bacteriuria 2 (40) . A prospective randomized study performed at the Mayo Clinic did enter adequate numbers of patients into a clinical study, and the authors of the report of this-research concluded that higher cure rates were achieved with a 10-day treatment course (44) . However, another study that enrolled adequate numbers of patients ahd was performed in Norway demonstrated that single-dose therapy was as effective as the conventional 10-day therapy (25) . (ii) Is single-dose therapy associated with an increased number of recurrent infections? Limited data do suggest that single-dose therapy exerts less suppression of enteric bacilli on the rectum, urethra, and vagina, thereby permitting perineal coloflization and increased numnbers of recurrent infections (11, 33) . (iii) Does failure with single-dose therapy result in serious sequelae when relapse occurs? There are no reports of bacteremia or need for hospitalization, but, rarely, relapsing infection has appeared as acute symptomatic pyelonephritis (25, 29) . (iv) Does inadequately treated pyelonephritis (which clinically presented as cystitis and was managed with single-dose drug therapy) become recalcitrant to subsequent conventional treatment? Limited data suggest that this can occur (43) .
A 3-day treatment course for women with acute bacterial cystitis was introduced into clinical practice 10 years ago to reduce costs and come to grips with the reality that patients often discontinued medication prematurely when therapy rapidly dissipated their disabling symptoms (10) . Two observations provided the scientific foundation for considering this abbreviated treatment course. Investigators had demonstrated thai successful treatment of a urinary tract infection was virtually always accompanied by sterilization of the urine within 24 to 48 h of the start of therapy. In addition, it was appreciated that most recurrent urinary tract infections in young women were new infections (reinfections rather than relapses) and that prevention of these recurrences would not be achieved by more prolonged drug therapy.
After the introduction of the 3-day course of antibacterial therapy, numerous investigators endorsed this treatment program for women with acute bacterial cystitis (13, 27, 30) . These researchers supported their position by publishing data indicating that the 3-day treatment course was as therapeutically effective as the more traditional 10-day therapy and that the short-duration treatment was associated with a reduced incidence of adverse drug reactions (25) .
A more critical assessment of these published studies indicates, however, that they contain some niethodologic and statistical deficiencies. Some studies included patients with asymptomatic bacteriuria, as well as acute pyelonephritis (13) . Some studies enrolled patients with bacteria resistant to the prescribed drug treatment (27) . Some studies failed to randomly allocate patients to the treatment programs being compared (10) . Most studies did not ascertain in a blinded manner the incidence of adverse drug reactions. Only one study included a sufficient number of patients to prevent type II error (25) .
It is apparent that there are adequate published studies in the literature to support the clinician's policy of prescribing either a 1-or a 3-day course of drug treatment for women with acute bacterial cystitis (25) . These abbreviated treatments are simple, relatively inexpensive, safer than, and, presumably, comparable in effectiveness to the standard 10-day course of drug treatment. However, it should be appreciated that there is a need for additional research incorporating adequate sample size, precise definition of diagnostic criteria, random allocation of treatmeht, and blind assessment of adverse drug reactions before these abbreviated drug programs are accepted as the preferred or accepted treatment.
URETHRAL SYNDROME Irritative voiding symptoms caused by low-count bacteriuria (<105 but .102 CFU/ml) or Chlamydia trachomatis define the urethral syndrome. On occasion, no infectious etiology is identified, particularly when pyuria is absent (52) .
A 10-day course of antimicrobial therapy effectively treats low-count bacteriuria caused by conventional uropathogens (E. coli, Staphylococcus saprophyticus) and C. trachomatis (51) . The latter organism causes the urethral syndrome rather exclusively in young, unmarried, sexually active women who have multiple sexual partners (3) . Limited data indicate that low-count bacteriuria can be eradicated by single-dose antimicrobial therapy (8, 54) .
RECURRENT INFECTIONS IN MEN
The traditional treatment of recurrent, invasive urinary tract infections in men, namely 10 to 14 days, has consistently failed to achieve impressive cure rates (21) . This disorder resembles what has been termed subclinical pyelorjephritis in women. Two studies, however, demonstrated that significantly improved therapeutic efficacy occurs when an extended course of therapy (6 to 12 weeks) is prescribed (20, 46) . In addition, the more prolonged treatment durations have not been associated with enhanced toxicity.
ASYMPTOMATIC BACTERIURIA IN THE ELDERLY
A consensus has emerged that asymptomatic bacteriuria in noncatheterized elderly patients does not require antimicrobial treatment. The following observations appear to support this position. For many of these elderly patients, bacteriuria is a transient event (4) . In addition, traditional courses of drug therapy have not only failed to achieve VOL. 31, 1987 prolonged sterility of the urinary tract, but they have often exposed aged patients to adverse effects. Most importantly, however, is the fact that there is no evidence that treatment of elderly bacteriuric patients reduces infectious morbidity or mortality (39) .
CHRONICALLY CATHETERIZED PATIENTS
Most investigators do not recommend vigorous attempts to rid the urine of bacteria in asymptomatic chronically catheterized patients (23) . These patients spontaneously demonstrate a continuously changing flora. In addition, antimicrobial agents administered to asymptomatic bacteriuric catheterized patients have not reduced the incidence of bacteriuria, the duration of bacteriuric episodes, the number of febrile days, or catheter obstructions. Antimicrobial agents are reserved for patients who experience symptomatic infection.
The optimum duration of antimicrobial therapy for patients with catheter-related urosepsis (fever or constitutional symptoms with or without bacteremia) remains unknown. A 10-day course of therapy appears to be adequate for patients who do not develop hematogenous dissemination to organs removed from the urinary tract (18) . Long-term sterility of the urinary tract is nfot achieved by the 10-day course of drug therapy, because recurrent bacteriuria invariably occurs in patients with chronic urethral catheters.
RENAL TRANSPLANT PATIENTS
Researchers have determined that treating renal transplant recipients who have urinary tract infections and immunologic evidence of tissue invasion (as identified by the ACB technique) for 6 weeks rather than the conventional 2 weeks reduces postoperative gram-negative bacteremic urosepsis and relapsing urinary tract infections (42) . Of additional interest is the fact that renal transplant recipients receiving immunosuppressive therapy to prevent graft rejection are capable of mounting an immune response directed against infecting uropathogens.
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